Effectiveness of intravenous XXXX as an adjunctive treatment in pediatric @entity159 .

@entity1 @entity4677 @entity410 @entity302 @entity159
OBJECTIVES: Intravenous @entity4677 (LEV) has been shown to be effective and safe in treating adults with @entity159 ( @entity159 ). We sought to investigate the efficacy and safety of intravenous LEV for pediatric @entity1 with refractory @entity159 . METHODS: We performed a retrospective medical-record review of pediatric @entity1 who were treated with intravenous LEV for refractory @entity159 . Clinical information regarding age, sex, @entity410 type, and underlying neurological status was collected. We evaluated other anticonvulsants that were used prior to administration of intravenous LEV and assessed loading dose, response to treatment, and any adverse events from intravenous LEV administration. RESULTS: Fourteen @entity1 (8 @entity1 and 6 @entity1 ) received intravenous LEV for the treatment of refractory @entity159 . The mean age of the @entity1 was 4.4    5.5 years (range, 4 days to 14.6 years). Ten of the @entity1 were neurologically healthy prior to the refractory @entity159 , and the other 4 had been previously diagnosed with @entity302 . The mean loading dose of intravenous LEV was 26    4.6 mg/kg (range, 20-30 mg/kg). @entity410 termination occurred in 6 (43%) of the 14 @entity1 . In particular, 4 (57%) of the 7 @entity1 younger than 2 years showed @entity410 termination. No immediate adverse events occurred during or after infusions. CONCLUSIONS: The current study demonstrated that the adjunctive use of intravenous LEV was effective and well tolerated in pediatric @entity1 with refractory @entity159 , even in @entity1 younger than 2 years. Intravenous LEV should be considered as an effective and safe treatment option for refractory @entity159 in pediatric @entity1 .
